Lung Cancer

The ALK inhibitor alectinib was highly active and well-tolerated in patients with ALK-rearranged, crizotinib-refractory, advanced non–small-cell lung cancer.

The FDA has approved necitumumab (Portrazza) in combination with chemotherapy for the treatment of patients with metastatic squamous non-small-cell lung cancer.

The FDA granted accelerated approval to osimertinib (Tagrisso), previously known as AZD9291, for treatment of advanced non-small-cell lung cancer (NSCLC) with the EGFR mutation T790M.

Early-stage lung cancer patients considered to be high risk for surgery can achieve good clinical outcomes with surgical resection, according to a new study.

Pembrolizumab, a PD-1 inhibitor, demonstrated better overall survival and progression-free survival vs docetaxel in non–small-cell lung cancer patients.

This slide show highlights some of the cutaneous side effects related to the use of epidermal growth factor receptor inhibitors (EGFRI).

A large cystic lung mass is found in the right upper lobe of a 3-year-old boy. After further evaluation, a biopsy is performed. What is your diagnosis?

A study looking at trends from 1985 to 2005 found that overall survival has increased in Medicare patients with small-cell lung cancer, and that treatment with chemotherapy is associated with improved survival.

Patients with ALK-rearranged non–small-cell lung cancer and brain metastases survive longer when treated with radiotherapy and tyrosine kinase inhibitors.

The US Food and Drug Administration expanded the approval of the anti-PD-1 immunotherapy agent nivolumab to include advanced non-squamous non-small-cell lung cancer.

In this interview we discuss a new trial involving the antibody-drug conjugate IMMU-132 as well as the future of chemotherapy in the treatment of lung cancer.

Patients with stage IV squamous cell lung cancer positive for an EGFR gene copy number biomarker saw a survival benefit when adding cetuximab to chemotherapy.

Seventy-five percent of patients diagnosed with metastatic adenocarcinoma of the lung before age 40 have an actionable mutation, according to preliminary results from the Genomics of Young Lung Cancer Study.

The incidence of NSCLC among self-reported never-smokers appears to be increasing, according to authors of two retrospective studies presented at the 2015 World Conference on Lung Cancer.

The newly revised 8th edition of the tumor, node, and metastasis (TNM) classification of lung cancer will improve the precision of staging and provide physicians with new data with which to treat patients.

The investigational agent IMMU-32 is well-tolerated in patients with previously-treated metastatic lung cancer, and interim survival data are “encouraging.”

Adding the angiogenesis inhibitor bevacizumab to standard cisplatin/pemetrexed chemotherapy prolonged survival by more than 2 months among patients with malignant pleural mesothelioma.

Postsurgical chemo-immunotherapy offers improved survival rates for patients with NSCLC, compared to adjuvant chemotherapy alone, according to a small phase III study.

Treatment with nivolumab and ipilimumab is clinically active and has a manageable safety profile for chemotherapy-naive patients diagnosed with advanced NSCLC.

Oncology teams need to spot emerging immune-related adverse events associated with immunotherapies early in order to avoid treatment discontinuation.

In this interview with Dr. Roy S. Herbst, we discuss the FDA approval of nivolumab for lung cancer as well as other immunotherapies under investigation for the treatment of lung cancer.

A new study identified the molecule known as N1,N12-diacetylspermine as a potential biomarker for early-stage non–small-cell lung cancer.

Differences in failure-to-rescue rates may explain a wide variation in mortality in patients undergoing lung cancer resection at different hospitals, according to a new study.

In this interview, Dr. Sumithra J. Mandrekar talks about umbrella versus basket trials in lung cancer.

New classification guidelines for histologic subtypes of stage I lung adenocarcinoma offer prognostic value, according to a recent study.

Limited resection is not as effective as lobectomy in older patients with early-stage lung cancer, according to a new study.

Six carbonyl compounds in exhaled breath can effectively discriminate between lung cancer patients and healthy patients, says a new study.

Adding tivantinib to erlotinib improved progression-free survival but not overall survival in patients with previously treated non-small-cell lung cancer.

This slide show provides information on the present and future of targeted therapies and immunotherapies based on a report from the IMS Institute for Healthcare Informatics.

Recent progress in lung cancer was a bright spot at the 2015 ASCO Annual Meeting. Several studies were presented that either are practice-changing or will likely lead to practice changes in the future.